|
CA672478A
(en)
*
|
|
1963-10-15 |
Heim Roger |
Psilocybin and psilocin
|
|
LU36879A1
(enExample)
|
1958-02-21 |
|
|
|
|
GB911946A
(en)
|
1958-02-21 |
1962-12-05 |
Sandoz Ltd |
Psilocybin and psilocin and processes for their preparation
|
|
US3075992A
(en)
*
|
1958-09-12 |
1963-01-29 |
Sandoz Ltd |
Esters of indoles
|
|
LU37646A1
(enExample)
*
|
1958-09-12 |
|
|
|
|
US3192111A
(en)
*
|
1959-02-16 |
1965-06-29 |
Sandoz Ltd |
Method of inducing therapeutic tranquilization with psilocybin and psilocin
|
|
IE24138L
(en)
|
1959-02-18 |
1959-08-21 |
Sandoz Ag |
Psilocybin and psilocin
|
|
JPS5576859A
(en)
|
1978-12-01 |
1980-06-10 |
Fujimoto Seiyaku Kk |
Novel preparation of 4-hydroxyindole
|
|
US4283709A
(en)
|
1980-01-29 |
1981-08-11 |
Summit Systems, Inc. (Interscience Systems) |
Cash accounting and surveillance system for games
|
|
JPS5728046A
(en)
|
1980-07-28 |
1982-02-15 |
Nissan Chem Ind Ltd |
Preparation of 4-substituted indole
|
|
US4499096A
(en)
|
1983-11-18 |
1985-02-12 |
Lotsof Howard S |
Rapid method for interrupting the narcotic addiction syndrome
|
|
EP0152379A3
(de)
|
1984-02-15 |
1986-10-29 |
Ciba-Geigy Ag |
Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
|
|
US4721612A
(en)
|
1984-04-12 |
1988-01-26 |
The Liposome Company, Inc. |
Steroidal liposomes
|
|
IL76591A0
(en)
|
1984-10-05 |
1986-02-28 |
Bioferon Biochem Substanz |
Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
|
|
US5785989A
(en)
|
1985-05-01 |
1998-07-28 |
University Utah Research Foundation |
Compositions and methods of manufacturing of oral dissolvable medicaments
|
|
US4587243A
(en)
|
1985-07-15 |
1986-05-06 |
Lotsof Howard S |
Rapid method for interrupting the cocaine and amphetamine abuse syndrome
|
|
EP0218479B2
(en)
|
1985-10-04 |
1998-08-05 |
South African Inventions Development Corporation |
Process for the production of a plant protein reagent, binding to tPA
|
|
US5725871A
(en)
|
1989-08-18 |
1998-03-10 |
Danbiosyst Uk Limited |
Drug delivery compositions comprising lysophosphoglycerolipid
|
|
AU645966B2
(en)
|
1989-09-05 |
1994-02-03 |
University Of Utah Research Foundation |
Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs
|
|
US5629307A
(en)
|
1989-10-20 |
1997-05-13 |
Olney; John W. |
Use of ibogaine in reducing excitotoxic brain damage
|
|
US5935925A
(en)
|
1990-05-08 |
1999-08-10 |
Synaptic Pharmaceutical Corporation |
Methods of treating migraine and compounds useful for such methods
|
|
US5626863A
(en)
|
1992-02-28 |
1997-05-06 |
Board Of Regents, The University Of Texas System |
Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
|
|
DK0554352T3
(da)
|
1990-10-19 |
2003-06-10 |
Univ New York |
Fremgangsmåde til transplantation af celler ind i hjernen og terapeutiske anvendelser derfor.
|
|
US5827819A
(en)
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
|
FR2675504B1
(fr)
|
1991-04-16 |
1995-01-27 |
Delalande Sa |
Derives d'aryl-3 oxazolidinone, leur procede de preparation et leur application en therapeutique.
|
|
US5468486A
(en)
|
1992-01-21 |
1995-11-21 |
The University Of Tennessee Research Corporation |
Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis
|
|
EP0566135A1
(en)
|
1992-04-17 |
1993-10-20 |
Takeda Chemical Industries, Ltd. |
Transmucosal composition comprising a peptide and a cytidine derivative
|
|
US5871710A
(en)
|
1992-09-04 |
1999-02-16 |
The General Hospital Corporation |
Graft co-polymer adducts of platinum (II) compounds
|
|
US5573776A
(en)
|
1992-12-02 |
1996-11-12 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
|
NZ258559A
(en)
|
1992-12-24 |
1996-07-26 |
Erba Carlo Spa |
Ergoline derivatives; their preparation and pharmaceutical compositions containing them
|
|
ES2068762B1
(es)
|
1993-07-21 |
1995-12-01 |
Lipotec Sa |
Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
|
|
US5545617A
(en)
|
1993-11-12 |
1996-08-13 |
The Schepens Eye Research Institute, Inc. |
Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
|
|
US20060019963A1
(en)
|
1994-06-17 |
2006-01-26 |
Smithkline Beecham Corporation |
Compounds
|
|
AU4613296A
(en)
|
1994-07-25 |
1996-04-19 |
Nda International, Inc. |
A method of treating chemical dependency in mammals and a composition therefor
|
|
US5874477A
(en)
|
1994-08-12 |
1999-02-23 |
The University Of Hawaii |
Method of treatment for malaria utilizing serotonin receptor ligands
|
|
US5696125A
(en)
|
1995-02-24 |
1997-12-09 |
Research Foundation Of The State University Of New York |
Substance abuse-induced hemorrhagic stoke in an animal model
|
|
US5643586A
(en)
|
1995-04-27 |
1997-07-01 |
Perricone; Nicholas V. |
Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
|
|
HUP9700322A3
(en)
|
1995-06-09 |
2001-03-28 |
Euro Celtique Sa |
Formulations and methods for providing prolonged local anesthesia
|
|
US5879690A
(en)
|
1995-09-07 |
1999-03-09 |
Perricone; Nicholas V. |
Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
|
|
DE19542281C2
(de)
|
1995-11-14 |
1997-12-04 |
Boehringer Ingelheim Kg |
Verwendung von Epinastin für die Behandlung der Migräne
|
|
FR2744364B1
(fr)
|
1996-02-07 |
1998-02-27 |
Rhone Poulenc Rorer Sa |
Application d'ureidoacetamides a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
|
|
FR2744361B1
(fr)
|
1996-02-07 |
1998-02-27 |
Rhone Poulenc Rorer Sa |
Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
|
|
FR2744363B1
(fr)
|
1996-02-07 |
1998-02-27 |
Rhone Poulenc Rorer Sa |
Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
|
|
FR2744362B1
(fr)
|
1996-02-07 |
1998-02-27 |
Rhone Poulenc Rorer Sa |
Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
|
|
AU2587297A
(en)
|
1996-03-25 |
1997-10-17 |
Eli Lilly And Company |
Method for treating pain
|
|
TW448171B
(en)
|
1996-06-06 |
2001-08-01 |
Yamanouchi Pharma Co Ltd |
Imidazole-substituted quinoxalinedione derivatives
|
|
AU3290397A
(en)
|
1996-06-10 |
1998-01-07 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5914129A
(en)
|
1996-07-23 |
1999-06-22 |
Mauskop; Alexander |
Analgesic composition for treatment of migraine headaches
|
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
|
US5958919A
(en)
|
1996-09-20 |
1999-09-28 |
Washington University |
Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
|
|
US5891885A
(en)
|
1996-10-09 |
1999-04-06 |
Algos Pharmaceutical Corporation |
Method for treating migraine
|
|
US6479074B2
(en)
|
1996-10-24 |
2002-11-12 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
|
US5804592A
(en)
|
1997-05-30 |
1998-09-08 |
Unimed Pharmaceuticals, Inc. |
Method for improving disturbed behavior and elevating mood in humans
|
|
EP1019041A4
(en)
|
1997-05-07 |
2002-04-17 |
Unimed Pharmaceutical Inc |
METHOD FOR IMPROVING DISTURBED BEHAVIOR AND STIMULATING MOOD IN HUMANS
|
|
WO1998059234A1
(en)
|
1997-06-24 |
1998-12-30 |
The University Of Wyoming |
Method and apparatus for detection of a controlled substance
|
|
GB9715082D0
(en)
|
1997-07-17 |
1997-09-24 |
Scherer Ltd R P |
Treatment of attention deficit hyperactivity disorder and narcolepsy
|
|
US20010004644A1
(en)
|
1997-07-21 |
2001-06-21 |
Levin Bruce H. |
Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
|
|
US7799337B2
(en)
|
1997-07-21 |
2010-09-21 |
Levin Bruce H |
Method for directed intranasal administration of a composition
|
|
WO1999009828A1
(en)
|
1997-08-25 |
1999-03-04 |
Pentech Pharmaceuticals, Inc. |
Method for amelioration of social phobia
|
|
ES2224430T3
(es)
|
1997-09-04 |
2005-03-01 |
Novoneuron Inc |
Noribogaina en el tratamiento del dolor y de la toxicomania.
|
|
US7220737B1
(en)
|
1997-09-04 |
2007-05-22 |
Novoneuron, Inc |
Noribogaine in the treatment of pain and drug addiction
|
|
DE19738855C2
(de)
|
1997-09-05 |
2001-01-04 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
|
|
US20030077227A1
(en)
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
|
US6228864B1
(en)
|
1997-10-28 |
2001-05-08 |
Vivus, Inc. |
Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
|
|
US6037346A
(en)
|
1997-10-28 |
2000-03-14 |
Vivus, Inc. |
Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
US5922341A
(en)
|
1997-10-28 |
1999-07-13 |
Vivus, Incorporated |
Local administration of pharmacologically active agents to treat premature ejaculation
|
|
WO1999021562A1
(en)
|
1997-10-28 |
1999-05-06 |
Asivi, Llc |
Treatment of female sexual dysfunction
|
|
ITTO980264A1
(it)
|
1998-03-26 |
1999-09-26 |
Silvio Rossi |
Applicazione di un estratto basico non quaternario della peschiera fuchsiaefolia ad attivita' antimalarica
|
|
EP1089736A2
(en)
|
1998-06-22 |
2001-04-11 |
Queen's University At Kingston |
Method and compositions for the treatment or amelioration of female sexual dysfunction
|
|
WO2000003746A2
(en)
|
1998-07-14 |
2000-01-27 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
|
AU4984899A
(en)
|
1998-07-14 |
2000-02-07 |
Adams Food Ltd. |
Nutritionally active composition for hardening fingernails
|
|
JP2002520353A
(ja)
|
1998-07-16 |
2002-07-09 |
マサチューセッツ インスティテュート オブ テクノロジー |
ストレスの処置のための組成物
|
|
CA2338326A1
(en)
|
1998-07-31 |
2000-02-10 |
Seth Lederman |
Use of moclobemide and metabolites for treating and preventing substance abuse
|
|
DK1112106T3
(da)
|
1998-09-18 |
2005-12-12 |
Alcon Mfg Ltd |
Serotonerge 5HT2-agonister til behandling af glaukom
|
|
US20060025387A1
(en)
|
1998-12-23 |
2006-02-02 |
Cytoscan Sciences Llc |
Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
|
|
JP2002535353A
(ja)
|
1999-01-29 |
2002-10-22 |
ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク |
医薬品組成物
|
|
WO2000050020A2
(en)
|
1999-02-24 |
2000-08-31 |
University Of Cincinnati |
Use of sulfamate derivatives for treating impulse control disorders
|
|
JP2003511347A
(ja)
|
1999-03-19 |
2003-03-25 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
ＩＩＩ型内皮細胞一酸化窒素合成酵素のＨＭＧ−ＣｏＡ還元酵素阻害物質による上方制御
|
|
US6217904B1
(en)
|
1999-04-06 |
2001-04-17 |
Pharmaquest Ltd. |
Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
NZ514466A
(en)
|
1999-04-07 |
2004-10-29 |
Pfizer Prod Inc |
Use of CYP2D6 inhibitors in combination therapies
|
|
US6126924A
(en)
|
1999-05-27 |
2000-10-03 |
Scales-Medeiros; Virginia A. |
Light responsive self-tanning products and methods for use
|
|
US6495498B2
(en)
|
1999-05-27 |
2002-12-17 |
Johnson & Johnson Consumer Companies, Inc. |
Detergent compositions with enhanced depositing, conditioning and softness capabilities
|
|
US6489341B1
(en)
|
1999-06-02 |
2002-12-03 |
Sepracor Inc. |
Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
|
|
US20080103179A1
(en)
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
|
US6500459B1
(en)
|
1999-07-21 |
2002-12-31 |
Harinderpal Chhabra |
Controlled onset and sustained release dosage forms and the preparation thereof
|
|
EP1250131A2
(en)
|
1999-08-23 |
2002-10-23 |
The Administrators Of The Tulane University Educational Fund |
Modulation of the blood-brain barrier transporter for leptin
|
|
US6204245B1
(en)
|
1999-09-17 |
2001-03-20 |
The Regents Of The University Of California |
Treatment of narcolepsy with immunosuppressants
|
|
AU8003800A
(en)
|
1999-10-08 |
2001-04-23 |
Joyce Corinne Bechthold |
Methods and compositions for treating neurobehavioral disorders
|
|
ES2162746B1
(es)
|
1999-10-21 |
2003-02-16 |
Lipotec Sa |
Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
|
|
US6693135B2
(en)
|
2000-01-10 |
2004-02-17 |
Nexmed (Holdings) Incorporated |
Prostaglandin compositions and methods of treatment for male erectile dysfunction
|
|
JP2003520228A
(ja)
|
2000-01-18 |
2003-07-02 |
バリー フォージ ファーマスーティカルズ インコーポレイテッド |
眼の成長及びニコチン性アンタゴニスト
|
|
US20030096831A1
(en)
|
2000-01-18 |
2003-05-22 |
Stone Richard A. |
Ocular growth and nicotinic antagonists
|
|
FR2804603B1
(fr)
|
2000-02-04 |
2004-01-23 |
Rhodia Chimie Sa |
Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques
|
|
US20020015730A1
(en)
|
2000-03-09 |
2002-02-07 |
Torsten Hoffmann |
Pharmaceutical formulations and method for making
|
|
AU2001243369A1
(en)
|
2000-03-14 |
2001-09-24 |
Massachusetts Institute Of Technology |
Composition and method to treat weight gain and obesity attributable to psychotropic drugs
|
|
AU2001247767A1
(en)
*
|
2000-03-27 |
2001-10-08 |
Pe Corporation (Ny) |
Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
|
|
DE10014588A1
(de)
|
2000-03-27 |
2001-10-04 |
Basf Ag |
Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
|
|
US6380176B2
(en)
|
2000-03-28 |
2002-04-30 |
Ajinomoto Co., Inc. |
Method for inhibiting non-intentional behavior with a running neuron inhibitory substance
|
|
DE10018834A1
(de)
|
2000-04-15 |
2001-10-25 |
Lohmann Therapie Syst Lts |
Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
|
|
AU6106801A
(en)
|
2000-04-28 |
2001-11-12 |
Gary W. Neal |
Trans-clitoral administration of therapy
|
|
ATE389455T1
(de)
|
2000-05-10 |
2008-04-15 |
Jagotec Ag |
Zerkleinerung mittels mahlkörper
|
|
US20070059367A1
(en)
|
2000-06-06 |
2007-03-15 |
Cherukuri S R |
Drug Delivery System and Associated Methods
|
|
US20020044962A1
(en)
|
2000-06-06 |
2002-04-18 |
Cherukuri S. Rao |
Encapsulation products for controlled or extended release
|
|
US20020019421A1
(en)
|
2000-07-05 |
2002-02-14 |
Roni Biberman |
Compositions and therapy for substance addiction
|
|
ATE480246T1
(de)
|
2000-07-19 |
2010-09-15 |
Univ Northwest |
Transport von nukleinsäuresubstanzen
|
|
EP1409530A2
(en)
|
2000-09-19 |
2004-04-21 |
Microbia, Inc. |
Modulation of secondary metabolite production by zinc binuclear cluster proteins
|
|
US9399050B2
(en)
|
2000-10-04 |
2016-07-26 |
Paul Edward Stamets |
Controlling insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi
|
|
US9474776B2
(en)
|
2000-10-04 |
2016-10-25 |
Paul Edward Stamets |
Integrative fungal solutions for protecting bees
|
|
US20030119884A1
(en)
|
2000-11-01 |
2003-06-26 |
Epstein Mel H. |
Methods and compositions for regulating memory consolidation
|
|
US20070100000A1
(en)
|
2000-11-01 |
2007-05-03 |
Epstein Mel H |
Methods of providing neuroprotection
|
|
AR031473A1
(es)
|
2000-11-20 |
2003-09-24 |
Lundbeck & Co As H |
Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
|
|
CA2359812C
(en)
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
|
US6495154B1
(en)
|
2000-11-21 |
2002-12-17 |
Vivus Inc. |
On demand administration of clomipramine and salts thereof to treat premature ejaculation
|
|
IL139975A0
(en)
|
2000-11-29 |
2002-02-10 |
Univ Ramot |
Anti proliferative drugs
|
|
AP2001002360A0
(en)
|
2000-11-30 |
2001-12-31 |
Pfizer Prod Inc |
Combination of gaba agonists and sorbitol dehydrogenase inhibitors.
|
|
EP1337272A2
(en)
|
2000-11-30 |
2003-08-27 |
Pfizer Products Inc. |
Combination of gaba agonists and aldose reductase inhibitors
|
|
US20050176790A1
(en)
|
2001-02-28 |
2005-08-11 |
Johannes Bartholomaus |
Pharmaceutical salts
|
|
US20020137785A1
(en)
|
2001-03-26 |
2002-09-26 |
George Kindness |
Inflammatory mechanism modulator composition and methods with anti-asthmatic properties
|
|
US20050096396A1
(en)
|
2002-03-28 |
2005-05-05 |
Emory University |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
|
EP1401410A4
(en)
|
2001-03-30 |
2009-03-04 |
Philadelphia Health & Educatio |
IMMUNOMODULATION AND EFFECT ON CELL PROCESSES INVOLVING RECEPTORS OF THE SEROTONIN FAMILY
|
|
US6632217B2
(en)
|
2001-04-19 |
2003-10-14 |
Microsolutions, Inc. |
Implantable osmotic pump
|
|
AU2002303577B2
(en)
|
2001-05-04 |
2006-06-08 |
Merck & Co., Inc. |
Method and compositions for treating migraines
|
|
US20030051728A1
(en)
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
|
US20040023952A1
(en)
|
2001-06-20 |
2004-02-05 |
Leventhal Audie G. |
Enhanced brain function by gaba-ergic stimulation
|
|
AU2002332942A1
(en)
|
2001-08-20 |
2003-03-03 |
Greiner Bio-One Gmbh |
Device and method for determining an analyte
|
|
US6541043B2
(en)
|
2001-08-28 |
2003-04-01 |
Dexgen Pharmaceuticals, Inc. |
Method and synergistic composition for treating attention deficit/hyperactivity disorder
|
|
WO2003020242A1
(en)
|
2001-08-29 |
2003-03-13 |
Srl Technologies, Inc. |
Sustained release preparations
|
|
EP2196217A1
(en)
|
2001-09-14 |
2010-06-16 |
Cytos Biotechnology AG |
Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
|
|
CA2492823A1
(en)
|
2001-09-14 |
2003-03-27 |
Martin F. Bachmann |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
|
US7544681B2
(en)
|
2001-09-27 |
2009-06-09 |
Ramot At Tel Aviv University Ltd. |
Conjugated psychotropic drugs and uses thereof
|
|
MXPA04002496A
(es)
|
2001-09-27 |
2004-05-31 |
Pharmacia Ab |
Composicion farmaceutica para el tratamiento de enfermedades urinarias.
|
|
US6592901B2
(en)
|
2001-10-15 |
2003-07-15 |
Hercules Incorporated |
Highly compressible ethylcellulose for tableting
|
|
US20060264508A1
(en)
|
2001-10-16 |
2006-11-23 |
Stone Richard A |
Modulation of ocular growth and myopia by gaba drugs
|
|
US20030082225A1
(en)
|
2001-10-19 |
2003-05-01 |
Mason Paul Arthur |
Sterile, breathable patch for treating wound pain
|
|
US7045543B2
(en)
|
2001-11-05 |
2006-05-16 |
Enzrel Inc. |
Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
|
|
EP1453468A4
(en)
|
2001-11-09 |
2005-11-23 |
Chiron Corp |
METHOD OF VACCINATION OF A HUMAN PATIENT TO PREVENT METASTATIC TUMORS
|
|
GB0127832D0
(en)
|
2001-11-20 |
2002-01-09 |
Jagotec Ag |
Method for the preparation of pharmaceutical nanosuspensions
|
|
AU2002352878B2
(en)
|
2001-11-27 |
2007-11-22 |
Merck Sharp & Dohme Corp. |
2-Aminoquinoline compounds
|
|
EP1451156A4
(en)
|
2001-11-27 |
2005-05-25 |
Merck & Co Inc |
4-AMINOCHINOLINVERBINDUNGEN
|
|
EP1509204A4
(en)
|
2001-11-29 |
2005-07-13 |
Rettenmaier & Soehne Gmbh & Co |
AGGLOMERATED PARTICLES WITH AN ACTIVE SUBSTANCE PREPARED WITH MELTED MICROCRYSTALLINE CELLULOSE
|
|
US7241797B2
(en)
|
2002-01-23 |
2007-07-10 |
University Of Cincinnati |
Method of increasing milk production
|
|
US20030171435A1
(en)
|
2002-01-23 |
2003-09-11 |
Drug Abuse Sciences, Inc. |
New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
|
|
CA2474190A1
(en)
|
2002-02-07 |
2003-08-14 |
Pharmacia Corporation |
Pharmaceutical dosage form for mucosal delivery
|
|
CA2474921A1
(en)
|
2002-02-07 |
2003-08-14 |
Pharmacia Corporation |
Pharmaceutical tablet
|
|
US20030153552A1
(en)
|
2002-02-14 |
2003-08-14 |
Mash Deborah C. |
Method of treating chemical dependency in mammals and a composition therefor
|
|
US7700561B2
(en)
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
|
DE10208335A1
(de)
|
2002-02-27 |
2003-09-04 |
Roehm Gmbh |
Arzneiform und Verfahren zu ihrer Herstellung
|
|
US20030199439A1
(en)
|
2002-04-22 |
2003-10-23 |
Simon David Lew |
Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
|
|
CA2483093A1
(en)
|
2002-04-24 |
2003-11-06 |
Cypress Bioscience, Inc. |
Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
|
|
WO2003092676A1
(en)
|
2002-04-29 |
2003-11-13 |
The General Hospital Corporation |
Compositions and methods for preventing abuse of orally administered medications
|
|
AUPS317102A0
(en)
|
2002-06-25 |
2002-07-18 |
Drug Delivery Solutions Pty Ltd |
Transdermal aerosol compositions
|
|
AU2003279750A1
(en)
|
2002-06-28 |
2004-01-19 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
|
|
US20040006043A1
(en)
|
2002-07-02 |
2004-01-08 |
Ramot University Authority For Applied Research & Industrial Development Ltd. |
Methods, pharmaceutical compositions and pharmaceutical kits for enhancing the therapeutic efficiency of cancer chemotherapeutic agents
|
|
US10738268B2
(en)
|
2016-08-21 |
2020-08-11 |
Insectergy, Llc |
Cannabis nanoemulsion methods
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
WO2004007538A2
(en)
|
2002-07-17 |
2004-01-22 |
Cytos Biotechnology Ag |
Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
|
|
MXPA04012010A
(es)
|
2002-07-18 |
2005-03-07 |
Cytos Biotechnology Ag |
Conjugados de hapteno-portador que comprende particulas similares a virus, y usos de los mismos.
|
|
US7838034B2
(en)
|
2002-07-30 |
2010-11-23 |
Grunenthal Gmbh |
Intravenous pharmaceutical form of administration
|
|
JPWO2004014429A1
(ja)
|
2002-08-09 |
2005-12-02 |
三菱ウェルファーマ株式会社 |
精神疾患発症脆弱性制御剤
|
|
US20030114512A1
(en)
|
2002-09-09 |
2003-06-19 |
Collier Robert J |
Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
|
|
WO2004025268A2
(en)
|
2002-09-13 |
2004-03-25 |
Carnegie Mellon University |
Optical biosensors and methods of use thereof
|
|
EP1542665A1
(en)
|
2002-09-19 |
2005-06-22 |
Merck & Co., Inc. |
Method for treating depression and/or anxiety
|
|
US6913768B2
(en)
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
|
DE10244504A1
(de)
|
2002-09-25 |
2004-04-08 |
Capsulution Nanoscience Ag |
Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
|
|
DK1551370T3
(da)
|
2002-10-11 |
2008-03-03 |
Idea Ag |
Aggregat med foröget deformerbarhed, som omfatter mindst tre amfipater, til forbedret transport gennem semipermeable barrierer og til ikke-invasiv lægemiddeltilförsel in vivo, især gennem huden
|
|
US7132122B2
(en)
|
2002-10-30 |
2006-11-07 |
The Regents Of The University Of California |
Direct micro-patterning of lipid bilayers using UV light and selected uses thereof
|
|
DE10250944B9
(de)
|
2002-10-31 |
2004-09-16 |
Cell Center Cologne Gmbh |
Verwendung eines Stifts zur Applikation von Pflege- oder Wirkstoffen in die Nase
|
|
US7670627B2
(en)
|
2002-12-09 |
2010-03-02 |
Salvona Ip Llc |
pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
|
|
CA2511606A1
(en)
|
2002-12-24 |
2004-07-15 |
Neurochem (International) Limited |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
|
ES2314362T3
(es)
|
2003-01-16 |
2009-03-16 |
Acadia Pharmaceuticals Inc. |
Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas.
|
|
WO2004064753A2
(en)
|
2003-01-23 |
2004-08-05 |
Acadia Pharmaceuticals Inc |
Use of n-desmethylclozapine to treat human neuropsychiatric disease
|
|
US20040186155A1
(en)
|
2003-01-30 |
2004-09-23 |
Dayno Jeffrey Marc |
Combination therapy for the treatment or prevention of migraine
|
|
EP1603548A4
(en)
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
|
|
US20040214215A1
(en)
|
2003-03-07 |
2004-10-28 |
Yu Ruey J. |
Bioavailability and improved delivery of alkaline pharmaceutical drugs
|
|
WO2004082624A2
(en)
|
2003-03-17 |
2004-09-30 |
Neurohealing Pharmaceuticals, Inc. |
Modafinil-based neurorehabilitation of impaired neurological function associated with injury
|
|
CN100560719C
(zh)
|
2003-03-26 |
2009-11-18 |
赛托斯生物技术公司 |
Melan-a肽类似物-病毒样颗粒偶联物
|
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
|
ES2380622T5
(es)
|
2003-05-29 |
2018-05-30 |
Shire Llc |
Compuestos de anfetamina resistentes al abuso
|
|
JP2006526652A
(ja)
|
2003-06-03 |
2006-11-24 |
ベス・イスラエル・ディーコニス・メディカル・センター |
血管狭窄を治療するための方法及び化合物
|
|
US20070065463A1
(en)
|
2003-06-20 |
2007-03-22 |
Ronald Aung-Din |
Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
|
|
EP1644335A4
(en)
|
2003-07-11 |
2008-06-04 |
Bristol Myers Squibb Co |
TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
|
|
JP4174016B2
(ja)
|
2003-07-11 |
2008-10-29 |
株式会社ビーエル |
競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
|
|
DE10334188B4
(de)
|
2003-07-26 |
2007-07-05 |
Schwarz Pharma Ag |
Verwendung von Rotigotin zur Behandlung von Depressionen
|
|
DE10338174A1
(de)
|
2003-08-20 |
2005-03-24 |
Lts Lohmann Therapie-Systeme Ag |
Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
|
|
US20050203011A1
(en)
|
2003-09-19 |
2005-09-15 |
The Regents Of The University Of California |
Mitigating symptoms and behaviors of substance abuse by modulating GDNF or BDNF pathway activity
|
|
US20050070501A1
(en)
|
2003-09-29 |
2005-03-31 |
New York Blood Center, Inc. |
Water dispersible film
|
|
SI1670444T1
(sl)
|
2003-10-03 |
2011-09-30 |
Veijlen N V |
Uporaba derivatov indolocetne kisline, ki zvišajo serumsko raven IGF-1,za pripravo terapevtskega sestavka za zdravljenje različnih bolezni
|
|
EP1670460B1
(en)
|
2003-10-10 |
2014-11-26 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
WO2005039502A2
(en)
|
2003-10-24 |
2005-05-06 |
Azopax Therapeutics Llc |
Macromer-melt formulations
|
|
US20070053954A1
(en)
|
2003-10-24 |
2007-03-08 |
Rowe Stephen C |
Macromer-melt formulations
|
|
JP2005132747A
(ja)
|
2003-10-29 |
2005-05-26 |
Ajinomoto Co Inc |
老齢伴侶動物の老化行動改善剤
|
|
WO2005058319A1
(en)
|
2003-12-16 |
2005-06-30 |
Cnsbio Pty Ltd |
Methods and compositions
|
|
US20050260258A1
(en)
|
2003-12-18 |
2005-11-24 |
The Texas A&M University System |
Use of vitelline protein B as a microencapsulating additive
|
|
WO2005063248A1
(en)
|
2003-12-22 |
2005-07-14 |
Sepracor Inc. |
Modafinil combination therapy for improving sleep quality
|
|
JP2007516275A
(ja)
|
2003-12-23 |
2007-06-21 |
ファイザー・プロダクツ・インク |
認知増強および精神病性障害のための治療的組合せ
|
|
GB0400802D0
(en)
|
2004-01-14 |
2004-02-18 |
Daniolabs Ltd |
Compounds for the treatment of disease
|
|
KR20060124731A
(ko)
|
2004-01-29 |
2006-12-05 |
뉴로몰레큘라 파마슈티칼스, 인코포레이티드 |
중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물
|
|
EP1727538A2
(en)
|
2004-02-13 |
2006-12-06 |
Neuromolecular Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
|
EP1734920A2
(en)
|
2004-02-13 |
2006-12-27 |
Neuromolecular Inc. |
Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
|
|
US7981441B2
(en)
|
2004-02-18 |
2011-07-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Drug delivery systems using mesoporous oxide films
|
|
US20050222270A1
(en)
|
2004-02-26 |
2005-10-06 |
Olney John W |
Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
|
|
FR2867075B1
(fr)
|
2004-03-03 |
2006-07-14 |
Ethypharm Sa |
Procede de preparation de microspheres biodegradables calibrees
|
|
CA2559207A1
(en)
|
2004-03-12 |
2005-09-29 |
The Mclean Hospital Corporation |
Salvinorin derivatives and uses thereof
|
|
US20060270592A1
(en)
|
2004-03-19 |
2006-11-30 |
Ophthalmic Research Associates, Inc. |
Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
|
|
CA2567249A1
(en)
|
2004-04-19 |
2006-10-05 |
Jds Pharmaceuticals, Llc |
Lithium combinations, and uses related thereto
|
|
WO2005102390A2
(en)
|
2004-04-22 |
2005-11-03 |
Pfizer Japan, Inc. |
Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
|
|
RU2253461C1
(ru)
|
2004-04-30 |
2005-06-10 |
Общество с ограниченной ответственностью "Паркинфарм" |
Фармацевтическая комбинация, оказывающая влияние на функционирование цнс, способ коррекции состояний, связанных с нарушениями функционирования цнс; фармацевтический набор; средство, способствующее проникновению через гематоэнцефалический барьер лекарственных субстанций и метаболитов; фармацевтическое средство для эндоназального применения
|
|
US20050255091A1
(en)
|
2004-05-14 |
2005-11-17 |
Loomis Gary L |
Hydrogels for biomedical applications
|
|
US20050261278A1
(en)
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
|
US20050265955A1
(en)
|
2004-05-28 |
2005-12-01 |
Mallinckrodt Inc. |
Sustained release preparations
|
|
NL1026634C2
(nl)
|
2004-07-12 |
2006-01-16 |
Willem Jacob Van Der Burg |
Psychofarmaceutisch preparaat en werkzame stof daarin.
|
|
US7799802B2
(en)
|
2004-08-03 |
2010-09-21 |
Institstute of Oriental Medical Science Inc. |
Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation
|
|
US20060030625A1
(en)
|
2004-08-06 |
2006-02-09 |
Cheryle Ram Hart |
Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
CN101065667B
(zh)
|
2004-09-24 |
2013-09-04 |
貝丝以色列女执事医疗中心 |
诊断和治疗妊娠并发症的方法
|
|
CA2582079A1
(en)
|
2004-09-27 |
2006-05-04 |
Organix, Inc. |
Indole compounds useful as serotonin selective agents
|
|
EP1799264A2
(en)
|
2004-10-08 |
2007-06-27 |
Neuromolecular Pharmaceuticals Inc |
Methods and compositions for treating migraine pain
|
|
EP2417986A1
(en)
|
2004-11-22 |
2012-02-15 |
Anadis Ltd. |
Bioactive compositions
|
|
FR2878161B1
(fr)
|
2004-11-23 |
2008-10-31 |
Flamel Technologies Sa |
Forme medicamenteuse orale, solide et concue pour eviter le mesusage
|
|
FR2878158B1
(fr)
|
2004-11-24 |
2009-01-16 |
Flamel Technologies Sa |
Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
|
|
US20060110327A1
(en)
|
2004-11-24 |
2006-05-25 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
|
US7294649B2
(en)
|
2004-12-17 |
2007-11-13 |
Roche Diagnostics Operatins, Inc. |
Methamphetamine derivatives and conjugates for immunoassay
|
|
CN101132777A
(zh)
|
2004-12-20 |
2008-02-27 |
科利吉姆制药公司 |
用于睡眠障碍的药物组合物
|
|
EP1844189B1
(en)
|
2005-01-10 |
2020-10-28 |
Smiths Detection Inc. |
Method for preparing a sampling swab
|
|
DE102005004343A1
(de)
|
2005-01-25 |
2006-08-10 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Behandlung von Phantomphänomenen
|
|
FR2881652B1
(fr)
|
2005-02-08 |
2007-05-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale microparticulaire anti-mesuage
|
|
US8318210B2
(en)
|
2005-02-28 |
2012-11-27 |
Neos Therapeutics, Lp |
Compositions and methods of making sustained release liquid formulations
|
|
EP1885342B8
(en)
|
2005-03-21 |
2016-06-22 |
Teva Czech Industries s.r.o. |
Crystallization inhibitor and its use in gelatin capsules
|
|
JP2008534498A
(ja)
|
2005-03-23 |
2008-08-28 |
ビーピーエスアイ ホールディングス，エルエルシー． |
凝集デンプン組成物
|
|
EP1863454A2
(en)
|
2005-03-28 |
2007-12-12 |
Orexo AB |
New pharmaceutical compositions useful in the treatment of migraine
|
|
US20060229293A1
(en)
|
2005-04-06 |
2006-10-12 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
|
|
JP2008535860A
(ja)
|
2005-04-08 |
2008-09-04 |
ニュー リヴァー ファーマシューティカルズ インク． |
乱用抵抗性アンフェタミンプロドラッグ
|
|
US8574604B2
(en)
|
2005-04-15 |
2013-11-05 |
Interface Biologics, Inc. |
Methods and compositions for the delivery of biologically active agents
|
|
EP1885708A2
(en)
|
2005-04-15 |
2008-02-13 |
Board of Trustees of Michigan State University |
Gpcr modulators
|
|
CA2605580A1
(en)
|
2005-04-22 |
2006-11-02 |
Wyeth |
Benzodioxane and benzodioxolane derivatives and uses thereof
|
|
US7439496B2
(en)
|
2005-05-06 |
2008-10-21 |
Smiths Detection Inc. |
Chemical identification of peroxide-based explosives
|
|
US8859585B2
(en)
|
2005-05-25 |
2014-10-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Scopolamine for the treatment of depression and anxiety
|
|
GB0511060D0
(en)
|
2005-05-31 |
2005-07-06 |
Novartis Ag |
Organic compounds
|
|
WO2006131923A2
(en)
|
2005-06-07 |
2006-12-14 |
Ramot At Tel Aviv University Ltd. |
Novel salts of conjugated psychotropic drugs and processes of preparing same
|
|
AU2006259224B2
(en)
|
2005-06-16 |
2012-08-23 |
Mohammed Saeed |
Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
|
|
US7645802B2
(en)
|
2005-06-27 |
2010-01-12 |
Biovail Laboratories International Srl. |
Bupropion hydrobromide and therapeutic applications
|
|
US9198862B2
(en)
|
2005-07-22 |
2015-12-01 |
Rubicon Research Private Limited |
Dispersible tablet composition
|
|
US8852638B2
(en)
|
2005-09-30 |
2014-10-07 |
Durect Corporation |
Sustained release small molecule drug formulation
|
|
US20070092586A1
(en)
|
2005-10-26 |
2007-04-26 |
Alamo Pharmaceuticals |
Compositions and methods for the administration psychotropic drugs which modulate body weight
|
|
DE102005055866A1
(de)
|
2005-11-23 |
2007-05-24 |
Hte Ag The High Throughput Experimentation Company |
Verfahren zur Herstellung von Aryl-Aryl gekoppelter Verbindungen
|
|
US20070190142A1
(en)
|
2006-01-21 |
2007-08-16 |
Abbott Gmbh & Co. Kg |
Dosage forms for the delivery of drugs of abuse and related methods
|
|
JP2009525124A
(ja)
|
2006-02-02 |
2009-07-09 |
メドロジックス・ディバイス・コーポレーション |
ゾル−ゲル組成物を含む生物活性材料送達系
|
|
US20070203216A1
(en)
|
2006-02-14 |
2007-08-30 |
Bjarke Ebert |
Method of treating inflammatory diseases
|
|
US20070190130A1
(en)
|
2006-02-16 |
2007-08-16 |
Mark William A |
Protein hydrolysate excipients
|
|
WO2007100913A2
(en)
|
2006-02-28 |
2007-09-07 |
The Regents Of The University Of California |
Genes differentially expressed in bipolar disorder and/or schizophrenia
|
|
AU2007223560A1
(en)
|
2006-03-01 |
2007-09-13 |
Tristrata, Inc. |
Composition and method for topical treatment of tar-responsive dermatological disorders
|
|
FR2898271B1
(fr)
|
2006-03-09 |
2009-01-16 |
Pierre Fabre Medicament Sa |
Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
|
|
AU2007229866A1
(en)
|
2006-03-22 |
2007-10-04 |
Mount Sinai School Of Medicine |
Intranasal administration of ketamine to treat depression
|
|
WO2006079999A2
(en)
|
2006-04-09 |
2006-08-03 |
Barth Frederik H |
Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
|
|
CA2648993A1
(en)
|
2006-04-14 |
2007-12-27 |
Roseita Esfand |
Grafted polymers and uses thereof
|
|
GB0608647D0
(en)
|
2006-05-02 |
2006-06-14 |
Haritou Susan J A |
Methods of diagnosis and treatment
|
|
US8846100B2
(en)
|
2006-05-12 |
2014-09-30 |
Shire Llc |
Controlled dose drug delivery system
|
|
MX2008014455A
(es)
|
2006-05-12 |
2008-11-27 |
Shire Llc |
Sistema de suministro de farmaco de dosis controlada.
|
|
HRP20120479T1
(hr)
|
2006-06-28 |
2012-07-31 |
Chelsea@Therapeutics@Inc |
Farmaceutski sastavi sa droksidopom
|
|
JP2010501026A
(ja)
|
2006-06-30 |
2010-01-14 |
インターフェース バイオロジクス，インコーポレーテッド |
生体応答性ポリマー
|
|
MX2009000641A
(es)
|
2006-07-17 |
2009-02-12 |
Univ Ramot |
Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns.
|
|
JP2009543812A
(ja)
|
2006-07-20 |
2009-12-10 |
キャスケイド・セラピューティクス・インコーポレイテッド |
５−ＨＴ２Ｃリガンドとしてのテトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピン
|
|
US20080026189A1
(en)
|
2006-07-27 |
2008-01-31 |
Chun-Wei Lin |
Thin key structure for generating dazzling light
|
|
CN103479603B
(zh)
|
2006-08-23 |
2016-06-22 |
蒙大拿大学 |
减轻神经元细胞损害的方法
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
WO2008026046A1
(en)
|
2006-08-30 |
2008-03-06 |
Pfizer Products Inc. |
Morpholine d3 dopamine antagonists
|
|
US20120058125A1
(en)
|
2006-08-31 |
2012-03-08 |
Biogen Idec Ma Inc. |
Methods relating to peripheral administration of nogo receptor polypeptides
|
|
AU2007299920A1
(en)
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
PPAR Mediated Modulation of Neurogenesis
|
|
US20080066739A1
(en)
|
2006-09-20 |
2008-03-20 |
Lemahieu Edward |
Methods and systems of delivering medication via inhalation
|
|
WO2008039179A1
(en)
|
2006-09-26 |
2008-04-03 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
|
|
WO2008038291A1
(en)
|
2006-09-27 |
2008-04-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
|
|
AU2007309390A1
(en)
|
2006-10-27 |
2008-05-02 |
Medivation Neurology, Inc. |
Methods and combination therapies for treating Alzheimer's disease
|
|
EP2089015B1
(en)
|
2006-10-27 |
2010-11-24 |
Janssen Pharmaceutica, N.V. |
Methods for treating disruptive behavior disorders
|
|
US20080103199A1
(en)
|
2006-10-31 |
2008-05-01 |
Haas Magali |
Treatment of pervasive developmental disorders
|
|
US20080293695A1
(en)
|
2007-05-22 |
2008-11-27 |
David William Bristol |
Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
|
|
US7718649B1
(en)
|
2006-11-10 |
2010-05-18 |
Pisgah Labs, Inc. |
Physical states of a pharmaceutical drug substance
|
|
US8653106B2
(en)
|
2010-07-30 |
2014-02-18 |
Pisgah Laboratories, Inc. |
Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
|
|
CN101594778A
(zh)
|
2006-12-11 |
2009-12-02 |
凯姆制药公司 |
苯丙胺的非标准氨基酸结合物及其制备和使用的方法
|
|
ES2302650B1
(es)
|
2007-01-11 |
2009-02-16 |
Tedec-Meiji Farma, S.A. |
Composicion de rapida desintegracion en la cavidad bucal.
|
|
WO2008095086A2
(en)
|
2007-01-31 |
2008-08-07 |
University Of Virginia Patent Foundation |
Topiramate plus naltrexone for the treatment of addictive disorders
|
|
CA2674020A1
(en)
|
2007-02-08 |
2008-08-14 |
Kempharm, Inc. |
Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
|
|
NZ579368A
(en)
|
2007-03-09 |
2012-03-30 |
Chelsea Therapeutics Inc |
Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
|
|
WO2008112773A2
(en)
|
2007-03-12 |
2008-09-18 |
Chelsea Therapeutics, Inc. |
Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
|
|
WO2008115797A1
(en)
|
2007-03-16 |
2008-09-25 |
Pavo, Inc. |
Therapeutic compositions and methods
|
|
DE102007014286A1
(de)
|
2007-03-19 |
2008-09-25 |
Universität Tübingen |
Fluorsubstituierte Amphetamine und Amphetaminderivate und deren Verwendung
|
|
AU2008232897B2
(en)
|
2007-03-30 |
2014-03-13 |
Philip Morris Products Sa |
Device and method for delivery of a medicament
|
|
AT505086B1
(de)
|
2007-04-02 |
2009-06-15 |
Planta Naturstoffe Vertriebsge |
Pharmazeutisches mittel gegen juckreiz und juckreizbedingten schmerz
|
|
WO2008122990A1
(en)
|
2007-04-04 |
2008-10-16 |
Almet Corporation Limited |
Compacting upflow extractor and method of using it
|
|
WO2008128193A1
(en)
|
2007-04-12 |
2008-10-23 |
Rutgers, The State University Of New Jersey |
Biodegradable polyanhydrides with natural bioactive molecules
|
|
EP2032586A2
(en)
|
2007-04-18 |
2009-03-11 |
Teva Pharmaceutical Industries Ltd. |
A process for preparing intermediates of hmg-coa reductase inhibitors
|
|
AU2008245662A1
(en)
|
2007-04-26 |
2008-11-06 |
Auspex Pharmaceuticals, Inc. |
Deuterium labelled ketamine
|
|
US9421266B2
(en)
|
2007-05-22 |
2016-08-23 |
Pisgah Laboratories, Inc. |
Safety of pseudoephedrine drug products
|
|
US10183001B1
(en)
|
2007-05-22 |
2019-01-22 |
Pisgah Laboratories, Inc. |
Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
|
|
MX2010001141A
(es)
|
2007-07-31 |
2010-03-01 |
Limerick Biopharma Inc |
Analogos fosforiladosde pirona y metodos.
|
|
HUE036004T2
(hu)
|
2007-08-03 |
2018-06-28 |
Richter Gedeon Nyrt |
Dopamin receptor ligandumokat tartalmazó gyógyszerkészítmények és kezelési eljárások dopamin receptor ligandumok alkalmazásával
|
|
NZ583192A
(en)
|
2007-08-06 |
2012-06-29 |
Biotie Therapies Inc |
Methods for treating dependence
|
|
FR2919861A1
(fr)
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
|
AU2016208412A1
(en)
|
2007-08-06 |
2016-08-18 |
Biotie Therapies, Inc. |
Methods for treating dependence
|
|
CA2694621C
(en)
|
2007-08-07 |
2015-01-06 |
Prosarix Limited |
Novel serotonergic modulators
|
|
US8067028B2
(en)
|
2007-08-13 |
2011-11-29 |
Confluent Surgical Inc. |
Drug delivery device
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
CA2701186C
(en)
|
2007-10-05 |
2017-09-19 |
Interface Biologics Inc. |
Oligofluorinated cross-linked polymers and uses thereof
|
|
US20110053859A1
(en)
|
2007-10-10 |
2011-03-03 |
The U. S. Government Respresented by the Department of Veterans Affairs |
Methods to reduce the effects of sleep deprivation
|
|
WO2009055001A2
(en)
|
2007-10-23 |
2009-04-30 |
Fred Hutchinson Cancer Research Center |
Methods of treating aging and methods of screening candidate agents therefor
|
|
WO2009061436A1
(en)
|
2007-11-06 |
2009-05-14 |
University Of Florida Research Foundation |
Compound for activating 5-ht2c receptors in combination with an amphetamine compound
|
|
DE102007063210A1
(de)
|
2007-12-20 |
2009-06-25 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Arzneimittel zur Behandlung von Phantomphänomenen
|
|
WO2009079765A1
(en)
|
2007-12-21 |
2009-07-02 |
Cascade Therapeutics Inc. |
Compounds with activity at the 5-ht2c receptor
|
|
WO2009089234A2
(en)
|
2008-01-07 |
2009-07-16 |
Auspex Pharmaceuticals |
Substituted dibenzhydrylpiperazines
|
|
JP5714910B2
(ja)
|
2008-01-09 |
2015-05-07 |
チャールストン ラボラトリーズ，インコーポレイテッド |
薬学的組成物
|
|
US8137690B2
(en)
|
2008-01-17 |
2012-03-20 |
Health Innovations, Llc |
Taste titration therapies
|
|
WO2009097596A1
(en)
|
2008-01-31 |
2009-08-06 |
Paul Griffin |
Compositions and methods for the treatment of chronic infections
|
|
US8329663B2
(en)
|
2008-01-31 |
2012-12-11 |
Paul Griffin |
Compositions and methods for the treatment of chronic infections
|
|
EP2237799B1
(en)
|
2008-02-01 |
2019-04-10 |
Ascendis Pharma A/S |
Prodrug comprising a self-cleavable linker
|
|
AU2009221419B2
(en)
|
2008-02-01 |
2013-09-26 |
Alpha-O Peptides Ag |
Self-assembling peptide nanoparticles useful as vaccines
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20090318527A1
(en)
|
2008-02-11 |
2009-12-24 |
Howard Sard |
Indole compounds and methods of use thereof
|
|
US8859579B2
(en)
|
2008-03-21 |
2014-10-14 |
Richard Andrew Sewell |
Compostions and methods for preventing and/or treating disorders associated with cephalic pain
|
|
AU2009228652A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Lonza Guangzhou Research And Development Center Ltd. |
Process for the synthesis of ethynylcyclopropane
|
|
US20170276676A1
(en)
|
2008-03-27 |
2017-09-28 |
Gus J. Slotman |
System for assessing drug efficacy and response of a patient to therapy
|
|
WO2009118763A1
(en)
|
2008-03-28 |
2009-10-01 |
Panacea Biotec Limited |
Multilayered pharmaceutical compositions and processes thereof
|
|
US20090252786A1
(en)
|
2008-03-31 |
2009-10-08 |
Christoph Hanz |
Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor
|
|
EP2106799A1
(en)
|
2008-03-31 |
2009-10-07 |
OWEN Holding LTD |
Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor
|
|
FR2930147B1
(fr)
|
2008-04-18 |
2013-02-08 |
Flamel Tech Sa |
Forme orale solide dotee d'un double profil de liberation
|
|
JP2011518881A
(ja)
|
2008-04-28 |
2011-06-30 |
ゾゲニクス インコーポレーティッド |
片頭痛の治療のための製剤
|
|
WO2009149252A1
(en)
|
2008-06-04 |
2009-12-10 |
Cornell University |
Vaccines for prevention and treatment of addiction
|
|
US10388179B2
(en)
|
2008-06-18 |
2019-08-20 |
Accenture Global Solutions Limited |
Analytics platform
|
|
BRPI0909936B1
(pt)
|
2008-06-19 |
2019-07-23 |
Lts Lohmann Therapie-Systeme Ag - Sociedade Alemã |
Composição para liberação transdérmica
|
|
EP2313037A1
(en)
|
2008-06-30 |
2011-04-27 |
Oron Zachar |
Dermal application of vasoconstrictors
|
|
US8617607B2
(en)
|
2008-07-10 |
2013-12-31 |
Tyrx, Inc. |
Sustained release formulations of psychoactive drugs
|
|
US9642819B2
(en)
|
2008-07-10 |
2017-05-09 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical |
Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
|
|
CN102170874A
(zh)
|
2008-08-06 |
2011-08-31 |
高思福斯中心（控股）有限公司 |
治疗精神病学障碍的组合物和方法
|
|
FR2935611B1
(fr)
|
2008-09-10 |
2010-10-15 |
Commissariat Energie Atomique |
Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
|
|
FR2936710B1
(fr)
|
2008-10-07 |
2011-01-07 |
Ceva Sante Animale |
Composition veterinaire antiprolactinique destinee aux ruminants
|
|
JP5675650B2
(ja)
|
2009-01-20 |
2015-02-25 |
ロサンゼルス バイオメディカル リサーチ インスティテュート アットハーバー− ユーシーエルエー メディカル センター |
向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
|
|
UA105657C2
(uk)
|
2009-02-27 |
2014-06-10 |
Хелсінн Терапьютікс (Ю.Ес.), Інк. |
Поліпшені способи лікування мігрені на основі анамореліну
|
|
WO2010124089A2
(en)
|
2009-04-22 |
2010-10-28 |
Synosia Therapeutics, Inc. |
Methods for treating dependence
|
|
US20120159656A1
(en)
|
2009-04-24 |
2012-06-21 |
Galenea Corp. |
Compositions and methods for evaluating cognitive defects
|
|
US20100303903A1
(en)
|
2009-05-26 |
2010-12-02 |
Shire Llc |
Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
|
|
GB201111485D0
(en)
|
2011-07-05 |
2011-08-17 |
Biocopea Ltd |
Drug composition and its use in therapy
|
|
US20110306596A1
(en)
|
2009-07-27 |
2011-12-15 |
Auspex Pharmaceuticals, Inc. |
Benzazepine inhibitors of gamma-secretase
|
|
WO2011020030A2
(en)
|
2009-08-13 |
2011-02-17 |
The General Hospital Corporation |
Methods and compositions to prevent addiction
|
|
US20110038915A1
(en)
|
2009-08-14 |
2011-02-17 |
Eduardo Jose Gonzalez |
Chewing Gum Formula for Enhancing Psycho-Spirituality
|
|
WO2011028875A1
(en)
|
2009-09-03 |
2011-03-10 |
Wake Forest University Health Sciences |
Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
|
|
WO2011027060A2
(fr)
|
2009-09-04 |
2011-03-10 |
Centre National De La Recherche Scientifique - Crns - |
Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
|
|
IN2012DN02078A
(enExample)
|
2009-10-16 |
2015-08-21 |
Dsm Ip Assets Bv |
|
|
FR2951378B1
(fr)
|
2009-10-16 |
2012-06-01 |
Flamel Tech Sa |
Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
|
|
EP2490677A2
(en)
|
2009-10-19 |
2012-08-29 |
Intec Pharma Ltd. |
Novel gastroretentive dosage forms of poorly soluble drugs
|
|
US8900603B2
(en)
|
2009-12-18 |
2014-12-02 |
Interface Biologics, Inc. |
Local delivery of drugs from self assembled coatings
|
|
HRP20171201T1
(hr)
|
2010-02-06 |
2017-10-06 |
Grünenthal GmbH |
Postupak kristalizacije i biodostupnost
|
|
WO2011109809A2
(en)
|
2010-03-05 |
2011-09-09 |
New Agriculture, Inc |
A novel composition of matter for delivering lipid-soluble materials, and a method for producing it
|
|
US20110217289A1
(en)
|
2010-03-05 |
2011-09-08 |
Basf Se |
Melt-Coated Dosage Forms
|
|
CN102892429B
(zh)
|
2010-03-17 |
2016-08-31 |
康奈尔大学 |
基于被破坏的腺病毒的抗滥用药物疫苗
|
|
WO2011138142A1
(en)
|
2010-05-07 |
2011-11-10 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Compositions and use of sulfasalazine
|
|
US9539193B2
(en)
|
2010-05-10 |
2017-01-10 |
Gfbiochemicals Limited |
Alkyl ketal esters as dispersants and slip agents for particulate solids, methods of manufacture, and uses thereof
|
|
US8362007B1
(en)
|
2010-05-11 |
2013-01-29 |
Demerx, Inc. |
Substituted noribogaine
|
|
US8765737B1
(en)
|
2010-05-11 |
2014-07-01 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
|
US20120108510A1
(en)
|
2010-05-20 |
2012-05-03 |
Emory University |
Methods of improving behavioral therapies
|
|
JP2012020991A
(ja)
|
2010-06-16 |
2012-02-02 |
Takasago Internatl Corp |
経皮吸収促進剤、及びこれを含有する皮膚外用製剤
|
|
US8802832B2
(en)
|
2010-06-22 |
2014-08-12 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
|
EP2595632A1
(en)
|
2010-07-23 |
2013-05-29 |
DemeRx, Inc. |
Noribogaine compositions
|
|
US20120039999A1
(en)
*
|
2010-08-11 |
2012-02-16 |
Ashish Chatterji |
Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
|
|
EP3333185A1
(en)
|
2010-08-20 |
2018-06-13 |
Heptares Therapeutics Limited |
Mutant gpcrs
|
|
RU2013112654A
(ru)
|
2010-08-30 |
2014-10-10 |
Президент Энд Феллоуз Ов Харвард Колледж |
Высвобождение, контролируемое сдвигом, для повреждений, вызванных стенозом, и тромболитических терапий
|
|
US20130310422A1
(en)
|
2010-09-01 |
2013-11-21 |
The General Hospital Corporation |
Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
|
|
US20120129834A1
(en)
|
2010-09-17 |
2012-05-24 |
Buck Institute For Research On Aging |
Serotonin receptor antagonists for use in the treatment of huntington's disease
|
|
DK2618826T3
(en)
|
2010-09-20 |
2016-08-01 |
A Carlsson Res Ab |
Phenylpiperdine FOR TREATMENT OF DEMENTIA
|
|
CA2816595C
(en)
|
2010-10-07 |
2018-11-27 |
Eaglepharma Pty Ltd |
Combination therapy for the treatment of depression and other non-infectious diseases
|
|
WO2012054815A1
(en)
|
2010-10-22 |
2012-04-26 |
Duke University |
Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
|
|
US20130230587A1
(en)
|
2010-11-10 |
2013-09-05 |
Rubicon Research Private Limited |
Sustained release compositions
|
|
TR201808178T4
(tr)
|
2010-11-15 |
2018-07-23 |
Neuroderm Ltd |
Aktif ajanların transdermal dağıtımı için bileşimler.
|
|
US9228991B2
(en)
|
2010-12-06 |
2016-01-05 |
Ramot At Tel-Aviv University Ltd. |
Methods and kits for detection of drugs
|
|
CA3114582A1
(en)
|
2010-12-22 |
2012-06-28 |
Syqe Medical Ltd. |
Method and system for drug delivery
|
|
EP2481740B1
(en)
|
2011-01-26 |
2015-11-04 |
DemeRx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
|
FR2971423B1
(fr)
|
2011-02-15 |
2014-01-10 |
Ceva Sante Animale |
Composition veterinaire antiprolactinique destinee aux ruminants
|
|
EP2691777A1
(en)
|
2011-03-28 |
2014-02-05 |
Flir Systems, Inc. |
Detection of analytes including drugs
|
|
US8742096B2
(en)
|
2011-03-28 |
2014-06-03 |
Demerx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
|
JOP20120083B1
(ar)
|
2011-04-05 |
2021-08-17 |
Otsuka Pharma Co Ltd |
توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
|
|
US20120282255A1
(en)
|
2011-04-07 |
2012-11-08 |
Greg Plucinski |
Methods and compositions for the treatment of alcoholism and alcohol dependence
|
|
KR20120128440A
(ko)
|
2011-05-17 |
2012-11-27 |
삼성전자주식회사 |
표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법
|
|
US20140163070A1
(en)
|
2012-05-17 |
2014-06-12 |
Bruce Roseman |
Treatment for cerebral palsy impaired speech in children
|
|
WO2012158892A2
(en)
|
2011-05-19 |
2012-11-22 |
Bruce Roseman |
A method of treating apraxia of speech in children
|
|
RU2013158449A
(ru)
|
2011-06-23 |
2015-07-27 |
Мэп Фармасьютикалс, Инк. |
Новые фторэрголиновые аналоги
|
|
US9040520B2
(en)
|
2011-09-15 |
2015-05-26 |
Demerx, Inc. |
Noribogaine salt ansolvates
|
|
WO2013061161A2
(en)
|
2011-10-28 |
2013-05-02 |
Green Bcn Consulting Services Sl |
New combination therapies for treating neurological disorders
|
|
AU2012335208B2
(en)
|
2011-11-07 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
|
FR2983409B1
(fr)
|
2011-12-06 |
2013-12-27 |
Ethypharm Sa |
Comprime susceptible de lutter contre le detournement par voie injectable
|
|
JP2015509076A
(ja)
|
2011-12-08 |
2015-03-26 |
デメレックス， インコーポレイテッド |
ノルイボガインの立体選択的全合成
|
|
JP2015509075A
(ja)
|
2011-12-09 |
2015-03-26 |
デメレックス， インコーポレイテッド |
ノルイボガインの硫酸エステル
|
|
EP2788003A4
(en)
|
2011-12-09 |
2015-05-27 |
Demerx Inc |
PHOSPHATESTER OF NORIBOGAIN
|
|
EP2607352A1
(en)
|
2011-12-22 |
2013-06-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pipecolate-diketoamides for treatment of psychiatric disorders
|
|
EP2610245A1
(en)
|
2011-12-28 |
2013-07-03 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pipecolate-sulfonamides for treatment of psychiatric disorders
|
|
CA2858820C
(en)
|
2012-01-25 |
2021-08-17 |
Demerx, Inc. |
Synthetic voacangine
|
|
WO2013112163A1
(en)
|
2012-01-25 |
2013-08-01 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
|
CA2858105A1
(en)
|
2012-01-25 |
2013-08-01 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
|
EP2649989B1
(en)
|
2012-04-13 |
2017-10-18 |
King Saud University |
Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
|
|
US20130295170A1
(en)
|
2012-05-03 |
2013-11-07 |
Kydes Pharmaceuticals Llc |
Compositions for control of drug abuse
|
|
US20130295016A1
(en)
|
2012-05-07 |
2013-11-07 |
David J. Gerber |
Signatures of electroencephalographic oscillations
|
|
KR102165348B1
(ko)
|
2012-05-09 |
2020-10-14 |
캔텍스 파마슈티칼즈, 인크. |
골수억제의 치료
|
|
WO2014008118A2
(en)
|
2012-07-02 |
2014-01-09 |
The General Hospital Corporation |
Method for concurrent treatment of pain and depression
|
|
US8784835B2
(en)
|
2012-07-02 |
2014-07-22 |
Trent Austin |
Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
|
|
EP2690102A1
(en)
|
2012-07-24 |
2014-01-29 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bicyclic aza-amides for treatment of psychiatric disorders
|
|
EP2884962B1
(en)
|
2012-08-17 |
2019-05-01 |
Smartek International LLC |
Preparation of desiccated liposomes for use in compressible delivery systems
|
|
CA2882870C
(en)
|
2012-08-24 |
2020-12-15 |
Integurx Therapeutics, Llc |
Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
|
|
US20140066881A1
(en)
|
2012-08-31 |
2014-03-06 |
Zoll Medical Corporation |
Cardiac resuscitation methods and kits
|
|
US20140100282A1
(en)
|
2012-10-10 |
2014-04-10 |
Patrick S L Wong |
Intranasal administration of pharmaceutical agents for treatment of neurological diseases
|
|
WO2014064703A1
(en)
|
2012-10-28 |
2014-05-01 |
Peritech Pharma Ltd. |
Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
|
|
WO2014078857A1
(en)
|
2012-11-19 |
2014-05-22 |
Regents Of The University Of Minnesota |
Ergoline derivatives as dopamine receptor modulators
|
|
EP2931291B1
(en)
|
2012-12-11 |
2021-10-20 |
The McLean Hospital Corporation |
Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
|
|
WO2014098877A1
(en)
|
2012-12-20 |
2014-06-26 |
Demerx, Inc. |
Substituted noribogaine
|
|
EP3485882A1
(en)
|
2013-01-25 |
2019-05-22 |
Case Western Reserve University |
Compositions for the treatment of pervasive development disorders
|
|
WO2014130581A1
(en)
|
2013-02-20 |
2014-08-28 |
Questcor Pharmaceuticals, Inc. |
Acth for treatment of migraine headache
|
|
KR20150136077A
(ko)
|
2013-03-10 |
2015-12-04 |
페리테크 파마 엘티디. |
국소 조성물 및 국소 질환의 치료 방법
|
|
WO2014153099A2
(en)
|
2013-03-14 |
2014-09-25 |
Pulmonary Analytics |
Method for using exhaled breath to determine the presence of drug
|
|
KR20240004497A
(ko)
|
2013-03-15 |
2024-01-11 |
멜리어 파마슈티칼스 투, 엘엘씨. |
시드노카브 또는 이의 약학적으로 허용되는 염을 포함하는 약학적 조성물 및 수면 장애를 치료하는 방법
|
|
WO2014142938A1
(en)
|
2013-03-15 |
2014-09-18 |
Aihol Corporation |
Pharmaceutical formulation containing glycosaminoglycan
|
|
CA2942638A1
(en)
|
2013-03-15 |
2014-09-18 |
Demerx, Inc. |
Method for noribogaine treatment of addiction in patients on methadone
|
|
WO2014146082A1
(en)
|
2013-03-15 |
2014-09-18 |
Bhl Patent Holdings Llc |
Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
|
|
WO2014176556A1
(en)
|
2013-04-26 |
2014-10-30 |
Express Diagnostics International, Inc. |
Portable testing system for detecting selected drugs or compounds in non-controlled environments
|
|
WO2014186623A2
(en)
|
2013-05-17 |
2014-11-20 |
Biomed Valley Discoveries |
Methods and compositions for the treatment of a chagas disease
|
|
AR096438A1
(es)
|
2013-05-29 |
2015-12-30 |
Gruenenthal Gmbh |
Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
|
|
CA2817728A1
(en)
|
2013-05-31 |
2014-11-30 |
Pharmascience Inc. |
Abuse deterrent immediate release formulation
|
|
NZ714817A
(en)
|
2013-06-04 |
2017-07-28 |
Vyome Biosciences Pvt Ltd |
Coated particles and compositions comprising same
|
|
US20140364367A1
(en)
|
2013-06-08 |
2014-12-11 |
Sedogen, Llc |
Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
|
|
EP2818177A1
(en)
|
2013-06-24 |
2014-12-31 |
Celica, D.O.O. |
Mechanism and drug targets for reducing cell edema (neuroprotection) and cytoplasmic excitability in astrocytes in normal and pathological states
|
|
AU2014284333B2
(en)
|
2013-07-03 |
2017-03-16 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse
|
|
PE20160556A1
(es)
|
2013-07-08 |
2016-06-11 |
Auspex Pharmaceuticals Inc |
Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos
|
|
US10624862B2
(en)
|
2013-07-12 |
2020-04-21 |
Grünenthal GmbH |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
|
US9770514B2
(en)
|
2013-09-03 |
2017-09-26 |
ExxPharma Therapeutics LLC |
Tamper-resistant pharmaceutical dosage forms
|
|
US10098893B2
(en)
|
2013-10-03 |
2018-10-16 |
Northwestern University |
Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
|
|
US9420970B2
(en)
|
2013-10-22 |
2016-08-23 |
Mindstrong, LLC |
Method and system for assessment of cognitive function based on mobile device usage
|
|
US9474481B2
(en)
|
2013-10-22 |
2016-10-25 |
Mindstrong, LLC |
Method and system for assessment of cognitive function based on electronic device usage
|
|
WO2015065546A2
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Abuse-deterrent dosage forms
|
|
WO2015065547A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
WO2015066344A1
(en)
|
2013-11-01 |
2015-05-07 |
Arena Pharmaceuticals, Inc. |
5-ht2c receptor agonists and compositions and methods of use
|
|
TW201605856A
(zh)
|
2013-11-01 |
2016-02-16 |
艾尼納製藥公司 |
５－ＨＴｃ受體促效劑
|
|
CN103535561A
(zh)
|
2013-11-05 |
2014-01-29 |
杨剑 |
饲养大猪用的牧草饲料
|
|
CN103549133A
(zh)
|
2013-11-05 |
2014-02-05 |
杨剑 |
有机猪牧草饲料
|
|
CN103751943B
(zh)
|
2014-01-13 |
2020-10-13 |
湖北及安盾消防科技有限公司 |
一种含有含氮类有机化合物的灭火组合物
|
|
AU2014379612A1
(en)
|
2014-01-24 |
2016-08-11 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
|
CN103773056B
(zh)
|
2014-01-24 |
2015-11-18 |
山东大学 |
高脆性透明类岩石材料试件制备方法
|
|
AU2015225442A1
(en)
|
2014-03-03 |
2016-10-20 |
Demerx, Inc. |
Therapeutic uses of ibogaine and related compounds
|
|
US20150258114A1
(en)
|
2014-03-13 |
2015-09-17 |
Demerx, Inc. |
Methods for acute and long-term treatment of substance abuse using ibogaine
|
|
WO2015187289A1
(en)
|
2014-06-03 |
2015-12-10 |
Pop Test Abuse Deterrent Technology Llc |
Drug device configured for wireless communication
|
|
EP3174893B1
(en)
|
2014-07-30 |
2020-05-06 |
Genome Protection, Inc. |
Flagellin compositions and uses
|
|
US10231651B2
(en)
|
2014-09-25 |
2019-03-19 |
Bae Systems Information And Electronic Systems Integration Inc. |
Gait authentication system and method thereof
|
|
US10058253B2
(en)
|
2014-11-11 |
2018-08-28 |
Zenmark, Llc |
System, method, and article for heart rate variability monitoring
|
|
GB201501312D0
(en)
|
2015-01-27 |
2015-03-11 |
Knauf Insulation And Knauf Insulation Llc And Knauf Insulation Gmbh And Knauf Insulation Doo Skofja |
Melter feeding system
|
|
US20180036303A1
(en)
|
2015-03-10 |
2018-02-08 |
Eleusis Benefit Corporation, Pbc |
Lsd for the treatment of alzheimer's disease
|
|
EP3275448B1
(en)
|
2015-03-24 |
2025-10-29 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
US10254298B1
(en)
|
2015-03-25 |
2019-04-09 |
National Technology & Engineering Solutions Of Sandia, Llc |
Detection of metabolites for controlled substances
|
|
AU2016242929A1
(en)
|
2015-03-31 |
2017-10-12 |
Paul Edward Stamets |
Antiviral activity from medicinal mushrooms and their active constituents
|
|
MX373319B
(es)
|
2015-04-27 |
2020-06-13 |
Arena Pharm Inc |
Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor.
|
|
CA2952818A1
(en)
|
2015-05-01 |
2016-11-10 |
Eran Eilat |
Compositions for the treatment of epistaxis
|
|
WO2016187277A1
(en)
|
2015-05-19 |
2016-11-24 |
Joseph Robert Knight |
Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
|
|
US20180147142A1
(en)
|
2015-05-19 |
2018-05-31 |
Joseph Robert Knight |
Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
|
|
US9737759B2
(en)
|
2015-07-17 |
2017-08-22 |
Genesant Technologies, Inc. |
Automatic application-based exercise tracking system and method
|
|
JP6789578B2
(ja)
|
2015-07-31 |
2020-11-25 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法
|
|
US9614734B1
(en)
|
2015-09-10 |
2017-04-04 |
Pearson Education, Inc. |
Mobile device session analyzer
|
|
US20180021326A1
(en)
|
2016-07-23 |
2018-01-25 |
Paul Edward Stamets |
Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
|
|
NZ750469A
(en)
|
2016-08-19 |
2023-03-31 |
Arena Pharm Inc |
5-ht2c receptor agonists and compositions and methods of use
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US20180195455A1
(en)
|
2017-01-12 |
2018-07-12 |
GM Global Technology Operations LLC |
Engine combustion phasing control during transient state
|
|
NL2018190B1
(en)
|
2017-01-18 |
2018-07-26 |
Procare Beheer B V |
Psilocybin or psilocin in combination with cannabinoid
|
|
JP7159174B2
(ja)
|
2017-02-02 |
2022-10-24 |
マックマスター、ユニバーシティー |
抗菌剤用増強剤としての重炭酸塩
|
|
JP7273731B2
(ja)
|
2017-02-09 |
2023-05-15 |
カームテック、エルエルシー |
シロシビン誘導体を含む組成物及び方法
|
|
WO2018145219A1
(es)
|
2017-02-09 |
2018-08-16 |
Serani Mostazal Jorge |
Composición farmaceutica para la prevención y tratamiento de las adicciones a traves de un contracondicionamiento aversivo
|
|
US20190142851A1
(en)
|
2017-11-16 |
2019-05-16 |
CaaMTech, LLC |
Compositions comprising a psilocybin derivative and a cannabinoid
|
|
CN108619214A
(zh)
|
2017-03-15 |
2018-10-09 |
王慎君 |
一种治疗肿瘤的药物
|
|
JP2020512358A
(ja)
|
2017-03-30 |
2020-04-23 |
オーハイ エナジェティクス ピービーシー |
健康を増進するための方法および組成物
|
|
JP2020516682A
(ja)
|
2017-04-07 |
2020-06-11 |
エイシア セラピューティクス， インコーポレイテッド |
ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
|
|
US20200147038A1
(en)
|
2017-04-20 |
2020-05-14 |
Eleusis Benefit Corporation, Pbc |
Assessing and treating psychedelic-responsive subjects
|
|
US20180343812A1
(en)
|
2017-05-31 |
2018-12-06 |
Insectergy, Llc |
Cannabis farming systems and methods
|
|
US20190246591A1
(en)
|
2017-05-31 |
2019-08-15 |
Insectergy, Llc |
Insect and cannabis production systems and methods
|
|
EP3629899A4
(en)
|
2017-06-02 |
2021-04-21 |
Northwestern University |
Thin, soft, skin-mounted microfluidic networks for detection and analysis of targets of interest in sweat
|
|
CN107252080A
(zh)
|
2017-07-12 |
2017-10-17 |
沈建国 |
一种麻菇酱油的配方
|
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
|
AU2018351515A1
(en)
|
2017-10-19 |
2020-05-21 |
Eleusis Health Solutions Us, Inc. |
Methods and systems for enhancing safety of psychedelic drug therapies
|
|
MA50786A
(fr)
|
2017-10-26 |
2022-04-27 |
Blumentech S L |
Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
|
|
US10703325B2
(en)
|
2017-11-27 |
2020-07-07 |
Autoliv Asp, Inc. |
Multi-chambered side airbag assemblies
|
|
AU2018381331A1
(en)
|
2017-12-04 |
2020-07-23 |
Victoria Cogger |
Compositions and methods for modulating liver endothelial cell fenestrations
|
|
FI128750B
(en)
|
2017-12-21 |
2020-11-30 |
Helsingin Yliopisto |
Methods for determining the therapeutic effect of fast-acting antidepressants and related individual antidepressant therapy
|
|
US20190224277A1
(en)
|
2018-01-22 |
2019-07-25 |
CyPhi LLC |
Bio-mimetic formulation
|
|
WO2019161050A1
(en)
|
2018-02-18 |
2019-08-22 |
Akili Interactive Labs, Inc. |
Cognitive platform including computerized elements coupled with a therapy for mood disorder
|
|
JP2021514682A
(ja)
|
2018-03-08 |
2021-06-17 |
ニュー アトラス バイオテクノロジーズ エルエルシー |
トリプタミンの生産方法
|
|
FI129102B
(en)
|
2018-03-19 |
2021-07-15 |
Teknologian Tutkimuskeskus Vtt Oy |
Heterological production of psilosybin
|
|
JP2021523228A
(ja)
|
2018-05-04 |
2021-09-02 |
パーセプション ニューロサイエンス，インコーポレイティド |
物質乱用の治療方法
|
|
CA3144504A1
(en)
|
2018-06-21 |
2019-12-21 |
Robert John Petcavich |
Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
|
|
WO2020024060A1
(en)
|
2018-08-01 |
2020-02-06 |
Mcmaster University |
Methods for inhibiting microbe growth
|
|
WO2020041329A1
(en)
|
2018-08-20 |
2020-02-27 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
WO2020053196A1
(en)
|
2018-09-10 |
2020-03-19 |
Universität Basel |
Method for the biocatalytic alkylation of a substrate
|
|
CN117100970A
(zh)
|
2019-01-04 |
2023-11-24 |
阿波罗神经科学公司 |
用于经皮振动的造波的系统和方法
|
|
CN114040767A
(zh)
|
2019-01-30 |
2022-02-11 |
钻石治疗公司 |
用于治疗心理、认知、行为和/或情绪障碍的包含5ht受体激动剂的方法和组合物
|
|
CN113993523A
(zh)
|
2019-04-17 |
2022-01-28 |
指南针探路者有限公司 |
用赛洛西宾治疗抑郁症和其他各种病症
|
|
US11766445B2
(en)
|
2019-07-18 |
2023-09-26 |
Concept Matrix Solutions |
Oral soft gel capsule containing psychedelic compound
|
|
EP4312995A1
(en)
|
2021-03-30 |
2024-02-07 |
COMPASS Pathfinder Limited |
Psilocybin compositions, methods of making and methods of using the same
|